EPIX acquires by private co for ~$1.91/sh +CVR—a 12% premium to Friday’s close (excluding the CVR): https://www.prnewswire.com/news-releases/essa-pharma-inc-announces-definitive-agreement-to-be-acquired-by-xenotherapeutics-inc-backed-by-xoma-royalty-corporation-in-all-cash-transaction-302504214.html The nominal deal value is $85M. EPIX has effectively been a shell company since its clinical failure in Nov 2024 (#msg-175318638).